SCRI Development Innovations, LLC clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 179 studies whose lead sponsor is SCRI Development Innovations, LLC. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 21, 2026.
Keep track of what changes. Save the SCRI Development Innovations, LLC studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesFocus areas
Conditions SCRI Development Innovations, LLC leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 179. Browse all 179 →
- A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07637578Phase 2
- A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)RecruitingNCT07011576Phase 2
- Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple MyelomaRecruitingNCT06974786Phase 2
- Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaRecruitingNCT05972135Phase 2
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingNCT05748834Phase 2
- BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)Active, not recruitingNCT06773910Phase 2
- A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerCompletedNCT04699630Phase 2
- Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 InhibitorCompletedNCT03977467Phase 2
- Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell LymphomaCompletedNCT04402138Phase 2
- A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT04200365Phase 2
- Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibWithdrawnNCT05948462Phase 2
- LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesTerminatedNCT02649673Phase 1
- Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02843074Phase 2
- Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression RiskCompletedNCT03436862Phase 2
- iCORE: Collaborative Orthopedics Outcomes RegistryWithdrawnNCT02422667
- Sarah Cannon Outcomes RegistryWithdrawnNCT02356822
- Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial CarcinomaTerminatedNCT02887248Phase 2
- A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid LeukemiaTerminatedNCT04209725Phase 2
- Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant CyclophosphamideWithdrawnNCT04361058Phase 1
- Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 MicrospheresTerminatedNCT02859064Phase 2
- Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine CancersCompletedNCT02318784Phase 2
- Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2
- Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver MetastasesCompletedNCT02195011Phase 2
- INC280 Combined With Bevacizumab in Patients With Glioblastoma MultiformeCompletedNCT02386826Phase 1
- Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine CarcinomaCompletedNCT00193531Phase 2
- Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal CancerCompletedNCT02317991Phase 2
- Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)CompletedNCT01990209Phase 2
- Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney CancerCompletedNCT00392821Phase 1/2
- Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal CancerCompletedNCT01154335Phase 1
- Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast CancerCompletedNCT01033032Phase 1/2
- First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLCCompletedNCT00456261Phase 2
- Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00600015Phase 2
- A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid TumorsCompletedNCT01226732Phase 1
- Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung CancerCompletedNCT00193427Phase 2
- Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00193414Phase 2
- Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00193479Phase 2
- Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal CancerCompletedNCT00393068Phase 2
- Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01496118Phase 1/2
- Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal CancerCompletedNCT00193219Phase 2
- Vinflunine in Hormone Refractory Prostate Cancer (HRPC)CompletedNCT00545766Phase 2
- Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung CancerCompletedNCT00741988Phase 2
- 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal CancerCompletedNCT00308516Phase 2
- RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBMCompletedNCT00805961Phase 2
- Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLCTerminatedNCT00960297Phase 2
- RAD001 Plus Bevacizumab in Metastatic MelanomaCompletedNCT00591734Phase 2
- Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast CancerCompletedNCT00629499Phase 2
- Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus CancerCompletedNCT00193128Phase 1/2
- Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast CancerCompletedNCT00193206Phase 2
- LBH589 Treatment for Refractory Clear Cell Renal CarcinomaCompletedNCT00550277Phase 2
- LBH589 in Refractory Myelodysplastic Syndromes (MDS)TerminatedNCT00594230Phase 2